Survival of Stage IIIA NSCLC Patients with Changes in N Stage after Neoadjuvant Chemoradiotherapy.
- Author:
Chi Hoon BAE
1
;
Seung Il PARK
;
Yong Hee KIM
;
Dong Kwan KIM
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Daegu Catholic University Medical Center, Catholic University of Daegu School of Medicine, Korea. chb1971@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Carcinoma, non-small cell, lung;
Survival;
Chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Chemoradiotherapy;
Disease Progression;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Mediastinoscopes;
Prognosis;
Recurrence;
Retrospective Studies;
Survival Rate;
Thoracoscopes
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2008;41(5):586-590
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Non-small cell lung cancer (NSCLC) patients histologically proven to have stage N2 disease by mediastinoscope or thoracoscope underwent subsequent neoadjuvant chemoradiotherapy. This study was designed to find out if there were any differences in survival or recurrence rates between N2 positive and N2 negative patients. MATERIAL AND METHOD: Between January 1998 and December 2005, we retrospectively analyzed 69 patients who were divided into three groups. Group A consisted of patients whose N stage was downstaged, group B of patients whose N stage was the same, and Group C of patients who could not undergo surgery because of disease progression during neoadjuvant chemoradiotherapy. We analyzed and compared the mean survival, three-year survival, mean disease-free survival, and three-year disease-free survival rates for the three groups. RESULT: There were no demographic differences among the groups. The mean survival was 58, 47, and 21 months for groups A, B, and C, respectively. The mean survival was longest in group A, but no statistically significant difference was found on A-B or B-C group comparison (p>0.05). However, a significant difference was noted between group A and group C (p:0.01). Three-year survival rates were 67%, 41%, and 21.6% for groups A, B, and C, respectively, with a statistical difference similar to that seen in mean survival. The mean disease-free survival was 44 months in group A and 45 months in group B, with no statistically significant difference noted. No significant differences were noted in the three-year disease-free survival rates (55.1%, 46.8%). CONCLUSION: There were no significant differences in survival or recurrence rates with changes in N stage after neoadjuvant chemoradiotherapy. However, mean survival, three-year survival, and three-year disease-free survival rates tended to be higher in downstaged patients. Nevertheless, the difference was statistically insignificant, and therefore further studies with more patients and longer follow-up are necessary to clarify the positive effects on the survival and prognosis of downstaged patients.
